מן הרשת 06.10.202411:41 Efficacy and safety of triplet nivolumab, relatlimab, and ipilimumab in advanced melanoma Results from RELATIVITY-048 Journal of Clinical Oncology
מן הרשת 06.10.202411:39 Efficacy and safety of NIVO + RELA + IPI in advanced melanoma Results from RELATIVITY-048 Journal of Clinical Oncology
מן הרשת 11.09.202411:58 Spinal Cord Atrophy and Brain Paramagnetic Rim Lesions in MS Association of Spinal Cord Atrophy and Brain Paramagnetic Rim Lesions With Progression Independent of Relapse Activity in People With MS Neurology
מן הרשת 11.09.202411:57 Serum NfL but not GFAP predicts cognitive decline in active progressive multiple sclerosis patients Objective: To investigate the association of sNfL and sGFAP with cognitive decline in MS patients at high risk for progressive pathology Mult Scler
מן הרשת 11.09.202411:56 Unveil the Pathobiological Foundations of Multiple Sclerosis Using the Progression Independent of Relapse Activity Framework to Unveil the Pathobiological Foundations of Multiple Sclerosis Neurology
מן הרשת 11.09.202411:54 Smouldering-Associated Worsening in Multiple Sclerosis An International Consensus Statement on Definition, Biology, Clinical Implications, and Future Directions Ann Neurol
מן הרשת 04.08.202411:00 Clinical Outcomes of Enfortumab Vedotin in Advanced Urothelial Carcinoma With Prior Avelumab Versus Pembrolizumab Therapy This study retrospectively evaluated whether enfortumab vedotin (EV) monotherapy is effective as a late-line treatment according to prior treatment type in patients with advanced urothelial carcinoma (UC) Uro Today
מן הרשת 04.08.202410:58 Early PSA Response by 6 Months is Predictive of Treatment Effect in Metastatic Hormone Sensitive Prostate Cancer An Exploratory Analysis of TITAN Trial Uro Today
מן הרשת 04.08.202410:57 Baseline Bone Pain and Survival in Newly Diagnosed Prostate Cancer In an analysis from the SWOG-1216 trial reported in JAMA Network Open, Gebrael et al found that the presence of bone pain at diagnosis was associated with poorer progression-free and overall survival in patients with newly diagnosed metastatic hormone-sensitive prostate cancer The ASCO Post
מן הרשת 04.08.202410:56 Can Mutations in DNA Damage Repair Genes Predict Cisplatin Response in Muscle-Invasive Urothelial Carcinoma? עבודה יפה מאוד עם קריאה להמשיך במעקב בלבד ללא ניתוח במטופלים עם מוטציות המתוארות The ASCO Post
מן הרשת 10.06.202412:34 Advancements in Urothelial Cancer Care: Optimizing Treatment for Your Patient HIGHLIGHTS FROM THE 2024 AMERICAN SOCIETY OF CLINICAL ONCOLOGY ANNUAL MEETING Oncology
מן הרשת 10.06.202412:34 HIGHLIGHTS FROM THE 2024 AMERICAN SOCIETY OF CLINICAL ONCOLOGY ANNUAL MEETING Uro Today
מן הרשת 10.06.202412:33 Long-Course vs Short-Course Androgen Deprivation Therapy Plus Postoperative Radiotherapy for Prostate Cancer Previous evidence supports androgen deprivation therapy (ADT) with primary radiotherapy as initial treatment for intermediate-risk and high-risk localised prostate cancer. However, the use and optimal duration of ADT with postoperative radiotherapy after radical prostatectomy remains uncertain Oncology
מן הרשת 10.06.202412:32 Short-Course vs No Androgen Deprivation Therapy Added to Postoperative Radiotherapy for Prostate Cancer Previous evidence indicates that adjuvant, short-course androgen deprivation therapy (ADT) improves metastasis-free survival when given with primary radiotherapy for intermediate-risk and high-risk localised prostate cancer. However, the value of ADT with postoperative radiotherapy after radical prostatectomy is unclear Oncology
מן הרשת 14.04.202411:58 לראשונה בביה"ח השרון: טיפול בכאבי כתפיים באמצעות שלט רחוק לראשונה במרפאות הכאב בבית החולים השרון מקבוצת כללית החלו לטפל בכאב עצבי כרוני בכתפיים ע"י השתלת אלקטרודה פריפרית לשיכוך כאב פת עכשיו
תגובות אחרונות